Current Report · Items 8.01 · 8-K/A
ABVC BioPharma, Inc.
ABVCNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On August 3, 2026, ABVC BioPharma, Inc. (the “Company”) determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. (the “Distribution”), which had been scheduled to occur on August 3, 2026. The Company has now determined that the Distribution will now occur on August 21, 2026.…
Filed Aug 12, 2026Accepted Aug 12, 2026, 11:50 AM EDTCIK 1173313Accession 0001213900-26-088165
Company context
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
Current securities
Disclosure sections
Items 8.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On August 3, 2026, ABVC BioPharma, Inc. (the “Company”)
determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. (the “Distribution”),
which had been scheduled to occur on August 3, 2026. The Company has now determined that the Distribution will now occur on August 21,
2026. The postponement provided the Company with additional time to complete certain administrative, regulatory and tax-related matters
necessary to effect the Distribution.
The Company coordinated with The Nasdaq Stock
Market LLC, The Depository Trust Company and the Company’s transfer agent regarding the revised distribution mechanics and the establishment
of the new distribution date of August 21, 2026.
The previously announced record date of July 24, 2026
remains unchanged, and the distribution ratio will remain 0.169464 ordinary shares of BioKey (Cayman), Inc. for each share of the Company’s
common stock held as of the record date. The previously announced ex-dividend date will no longer apply and will be revised in connection
with the new distribution date of August 21, 2026.
The Company intends to announce the corresponding
ex-dividend date after such date has been finalized and the remaining administrative, regulatory, and tax-related matters have been completed.